BRIDGEWATER, N.J., May 2, 2012 /PRNewswire/ -- Sanofi US
announced today that the iBGStar® Blood Glucose Monitoring System,
consisting of the iBGStar® blood glucose meter and iBGStar®
Diabetes Manager App, is commercially available in the
U.S. iBGStar® is the first Food and Drug Administration
(FDA) cleared blood glucose meter that directly connects to the
iPhone® and iPod touch®, offering accurate blood glucose monitoring
that seamlessly integrates into the lives of people with diabetes.
iBGStar® is available for purchase at Apple® Retail
Stores and all Walgreens stores nationwide, online at Apple.com,
Walgreens.com and through Diabetic Care Services.
To view the multimedia assets associated with this release,
please click:
http://www.multivu.com/mnr/46108-sanofi-ibgstar-blood-glucose-monitoring-system
"Many people with diabetes today rely both on their
iPhone® or iPod touch® and blood glucose monitors as
important parts of their daily lives," said Naina Sinha, MD, an in-patient diabetes
attending physician and assistant professor of medicine at a
leading academic medical center and university in New York City. "By combining these two
essential tools, iBGStar® makes it possible to provide blood
glucose tracking, monitoring and reporting together in a new
way."
About iBGStar®
When iBGStar® is directly connected to an iPhone® or iPod
touch® and used with the iBGStar® Diabetes Manager App, blood
glucose results are presented on the Multi-Touch display quickly
after monitoring.
iBGStar® can also be used independently to measure blood glucose
levels; results can be synchronized later to an iPhone® or iPod
touch®. iBGStar® and BGStar® Blood Glucose Test Strips, which are
used with iBGStar®, are available at all Walgreens stores
nationwide and online at Walgreens.com and through Diabetic Care
Services. These test strips may be covered under certain health
insurance plans so individuals should check directly with their
provider.
The iBGStar® Diabetes Manager App has a range of features and
multiple views for analyzing glucose patterns on-the-go. Visual
graphs and statistics can help people record and track their
readings, carbohydrate intake, insulin doses (if taking insulin)
and more. Color-coded scorecards show individual monitoring results
for easy identification of high or low blood glucose levels. A
'share' function allows specific data to be sent via e-mail to
caregivers and/or healthcare teams. The iBGStar® Diabetes Manager
App is available for free from the App Store on iPhone® and iPod
touch® or at www.itunes.com/appstore.
"Sanofi is pleased to launch iBGStar®, which expands our
diabetes portfolio as we pursue comprehensive disease management
offerings and further illustrates our commitment to developing
innovative solutions that help improve the lives of people with
diabetes," commented Dennis
Urbaniak, Vice President, Head of U.S. Diabetes, Sanofi US.
"The iBGStar® Blood Glucose Monitoring System will help people
living with diabetes check their blood sugar and communicate with
their healthcare teams, using mobile technologies that have become
central to so many people's lives."
In March 2010, Sanofi and
AgaMatrix signed an agreement for the development, supply and
commercialization of Blood Glucose Monitoring solutions. iBGStar®
is a result of this agreement.
iBGStar® received the Good Design™ Award in 2011 for outstanding
product design in the medical category from the Chicago Athenaeum
of Architecture and Design and the European Centre for Architecture
Art Design and Urban Studies. Additionally, iBGStar® received the
red dot design award in 2011 for outstanding product design in the
life science and medicine category. The red dot design award is one
of the most renowned international design competitions
(www.red-dot.de/presse), with almost 14,000 entries from 68
countries in 2010 alone. Winners are considered to be the best
design in the industry worldwide.
Apple®, iPhone® and iPod touch® are
trademarks of Apple Inc, registered in the U.S. and other
countries. App Store is a service mark of Apple Inc. Content
purchased from the iTunes Store is for personal lawful use only.
Don't steal music.
For more information, visit www.ibgstar.us.
About the Sanofi Diabetes Division
Sanofi strives to help people manage the complex challenges
of diabetes by delivering innovative, integrated and personalized
solutions. Driven by valuable insight that comes from listening to
and engaging with people living with diabetes, the Company is
forming partnerships to offer diagnostics, therapies, services, and
devices, including innovative blood glucose monitoring systems.
Sanofi markets both injectable and oral medications for people with
type 1 or type 2 diabetes. Investigational compounds in the
pipeline include an injectable GLP-1 agonist being studied as a
single agent, in combination with basal insulin, and/or in
combination with oral antidiabetic agents.
Important Information
The iBGStar® meter and lancing device are for
single patient use. Do not share them with anyone including other
family members. Do not use on multiple patients. All parts of the
kit are considered biohazardous and can potentially transmit
infectious diseases, even after you have performed cleaning and
disinfection.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers,
develops and distributes therapeutic solutions focused on patients'
needs. Sanofi has core strengths in the field of healthcare with
seven growth platforms: diabetes solutions, human vaccines,
innovative drugs, consumer healthcare, emerging markets, animal
health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is the holding company of a consolidated group of
subsidiaries and operates in the United
States as Sanofi US, also referred to as sanofi-aventis U.S.
LLC. For more information on Sanofi US, please visit
http://www.sanofi.us or call 1-800-981-2491.
Forward Looking Statements
This press release contains forward-looking statements
as defined in the Private Securities Litigation Reform Act of 1995,
as amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product
development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words "expects", "anticipates", "believes", "intends",
"estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
the Group's ability to benefit from external growth opportunities,
trends in exchange rates and prevailing interest rates, the impact
of cost containment policies and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under "Risk Factors" and "Cautionary
Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2011. Other than as required by
applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.
US.BGM.12.02.076
SOURCE Sanofi US
